Status:
TERMINATED
A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection
Lead Sponsor:
Shionogi
Conditions:
Postoperative Gastrointestinal Dysfunction
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The objective of this study is to compare the efficacy of naldemedine versus placebo and to assess its effect on the time to gastrointestinal (GI) recovery following surgeries that include bowel resec...
Eligibility Criteria
Inclusion
- Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery under general anesthesia:
- partial small or large bowel resection with primary anastomosis
- radical cystectomy requiring bowel transection with primary anastomosis
- Planned to be managed postoperatively with an enhanced recovery protocol, which, at a minimum, includes all of the following elements:
- early removal of the nasogastric tube, which is defined as removal of the nasogastric tube at the end of surgery
- early ambulation, which is defined as ambulation on Day 1
- early diet advancement on Day 1
- Planned to receive primary postoperative pain management with opioid analgesia administered by any route.
- American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a normal healthy participant, a participant with mild systemic disease, and a participant with systemic disease, respectively).
Exclusion
- Scheduled to undergo a total colectomy or any procedure that results in a colostomy or ileostomy.
- Scheduled for endoscopic or laparoscopic surgery.
- Complete bowel obstruction.
- Complicated inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).
- More than 2 major abdominal surgery (for example, gastrectomy, gastric bypass, gastric sleeve, lap banding, pancreatic resection, hepatectomy, intestinal transplant).
- More than 3 doses of an opioid (regardless of the route of administration) during the 7 days prior to surgery.
- Pregnancy or lactation.
- Presence of peritoneal catheter (for example, for dialysis or chemotherapy).
Key Trial Info
Start Date :
November 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 4 2021
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04355169
Start Date
November 6 2020
End Date
January 4 2021
Last Update
January 18 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner University Medical Center - Tucson
Tucson, Arizona, United States, 85719
2
Norton Hospital
Louisville, Kentucky, United States, 40202
3
University of Louisville Hospital
Louisville, Kentucky, United States, 40202
4
University of Louisville Division of Surgery
Louisville, Kentucky, United States, 40208